Tolerogenic Dendritic Cells Generated with Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis through Modulation of Th17/Treg Balance

@article{Zhou2016TolerogenicDC,
  title={Tolerogenic Dendritic Cells Generated with Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis through Modulation of Th17/Treg Balance},
  author={Yan Zhou and Xiao Leng and Shasha Luo and Zhiwei Su and Xingyan Luo and Huijie Guo and Chunfen Mo and Qiang Zou and Yang Liu and Yantang Wang},
  journal={Journal of Immunology Research},
  year={2016},
  volume={2016}
}
It is well known that dendritic cells (DCs) play a pivotal role in triggering self-specific responses. Conversely, tolerogenic DCs (tolDCs), a specialized subset, induce tolerance and negatively regulate autoreactive responses. Tofacitinib, a Janus kinase inhibitor developed by Pfizer for treatment of rheumatoid arthritis, is probable to be a promising candidate for inducing tolDCs. The aims of this study were to evaluate the effectiveness of tolDCs induced by tofacitinib in a myelin… Expand
Tolerogenic Dendritic Cells Induced by BD750 Ameliorate Proinflammatory T cell Responses and Experimental Autoimmune Encephalitis in Mice
TLDR
Treatment with BD750 induced tolDC that inhibited proinflammatory T cell immunity in vitro and in vivo and may be valuable for development of new therapies for EAE and other autoimmune diseases. Expand
Regulatory Dendritic Cells Induced by K313 Display Anti-Inflammatory Properties and Ameliorate Experimental Autoimmune Encephalitis in Mice
TLDR
K313-modified DCregs show anti-inflammatory properties in vitro and have a significant positive effect on the EAE disease in vivo, indicating that K313-inducedDCregs pulsed with auto-antigen might have potential use as a therapeutic approach for autoimmune inflammation of the central nervous system. Expand
Ruxolitinib attenuates experimental autoimmune encephalomyelitis (EAE) development as animal models of multiple sclerosis (MS).
TLDR
The results show that ruxolitinib may be a promising therapeutic strategy for multiple sclerosis and markedly decreased the expression of Th17 related transcription factor, RORɣt, whereas FOXP3 expression associated with Treg differentiation was increased. Expand
A short course of Tofacitinib sustains the immunoregulatory effect of CTLA4-Ig in presence of inflammatory cytokines and promotes long-term survival of murine cardiac allografts
TLDR
A powerful synergism between CTLA4-Ig and Tofacitinib is demonstrated and their combined use is suggested to be a promising strategy for improved management of transplanted patients. Expand
Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells
TLDR
Treatment with tofacitinib inhibited the development of EAU, reduced the production of IFN-γ, but had essentially no effect on theproduction of IL-17 and its transcription factor, RORγt. Expand
Effect of immune tolerance induced by immature dendritic cells and CTLA4-Ig on systemic lupus erythematosus: An in vivo study.
TLDR
Combined treatment with IL-10-DCs and CTLA4-Ig strongly induced immune tolerance in mice with SLE, as indicated by the significantly reduced levels of urine protein, anti-nuclear antibody, double-stranded DNA and IL-17A. Expand
A short course of tofacitinib sustains the immunoregulatory effect of CTLA4‐Ig in the presence of inflammatory cytokines and promotes long‐term survival of murine cardiac allografts
  • M. Iglesias, S. Khalifian, +5 authors G. Raimondi
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2020
TLDR
A powerful synergism between CTLA4‐Ig and tofacitinib is demonstrated and their combined use is suggested to be a promising strategy for improved management of transplanted patients. Expand
Natural and Induced Tolerogenic Dendritic Cells
TLDR
The mechanisms and functions of natural and induced tolerogenic DCs are discussed and further insight is offered into how their possible manipulations may ultimately lead to more precise treatments for various immune-mediated conditions and diseases. Expand
Recent Advances in Antigen-Specific Immunotherapies for the Treatment of Multiple Sclerosis
TLDR
The present study attempts to highlight the various antigen-specific immunotherapies developed so far for the treatment of multiple sclerosis, focusing on the outcome of their recent preclinical and clinical evaluation, and to shed light on the mechanisms involved in the immunopathogenesis and treatment ofmultiple sclerosis. Expand
Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy
TLDR
This review analyzes current MS treatments as well as different cell-based therapies that have been proposed to restore homeostasis in MS patients (tolerogenic dendritic cells, regulatory T cells, mesenchymal stem cells, and vaccination with T cells). Expand
...
1
2
3
...

References

SHOWING 1-10 OF 75 REFERENCES
Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients
TLDR
Treatment with vitD3 f-tolDC-MOG was effective in ameliorating clinical signs of mice with EAE, inhibiting antigen-specific reactivity and inducing Treg, and is a potential strategy to arrest the autoimmune destruction in MS patients. Expand
Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis
Autoimmune diseases including multiple sclerosis (MS) are the result of an imbalanced immune tolerance network. Dendritic cells (DCs) are key players in both initiating immunity (immunogenic DCs) andExpand
Stable antigen‐specific T‐cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients
TLDR
Results suggest that myelin peptide‐loaded tolDCs may be a powerful tool for inducing myelin‐specific tolerance in RR‐MS patients. Expand
Midkine Inhibits Inducible Regulatory T Cell Differentiation by Suppressing the Development of Tolerogenic Dendritic Cells
TLDR
It is demonstrated that MK was produced by inflammatory cells, in particular, CD4+ T cells under inflammatory conditions, and suggested that MK aggravates EAE by suppressing DCreg development, thereby impairing the Treg population. Expand
CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
TLDR
The engineered Tregs suppressed ongoing encephalomyelitis as demonstrated by reduced disease symptoms as well as decreased IL-12 and IFNgamma mRNAs in brain tissue and efficiently suppressed ongoing inflammation leading to diminished disease symptoms. Expand
Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses.
TLDR
Treatment with type II collagen-pulsed tolerogenic DCs decreases the proportion of Th17 cells in arthritic mice and simultaneously reduces the severity and progression of arthritis. Expand
Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity.
TLDR
The purpose of this paper is to give a general overview of the current literature on the significance of tDCs in tolerance maintenance to self and innocuous antigens, the most relevant alterations involved in the pathophysiology of ADs, the cellular and molecular mechanisms involved in their tolerogenic function and the current strategies used to exploit their toleranceogenic potential. Expand
Tolerogenic dendritic cells modified by tacrolimus suppress CD4(+) T-cell proliferation and inhibit collagen-induced arthritis in mice.
TLDR
Tolerogenic dendritic cells modified by tacrolimus suppressed CD4(+) T cell proliferation and inhibited collagen-induced arthritis, suggesting the potential use of tDCs as a therapeutic approach for autoimmune arthritis. Expand
Role of the Immunogenic and Tolerogenic Subsets of Dendritic Cells in Multiple Sclerosis
TLDR
The immunogenic and tolerogenic roles of Dendritic cells in MS are summarized and medicinal drugs that may affect functions of DCs and have been applied in clinic for MS treatment are reviewed. Expand
The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells
TLDR
Tofacitinib, a JAK1/JAK3 inhibitor, affected the activities of human DCs and decreased CD80/CD86 expression and T cell stimulatory capability through suppression of type I IFN signalling, suggesting a novel mode of action and a pivotal role for JAKs in the differentiation of DCs. Expand
...
1
2
3
4
5
...